Aprogen Medicines Inc. (KRX:007460)
South Korea · Delayed Price · Currency is KRW 450.00
-27.00 (-5.66%)
At close: Feb 20, 2026
Aprogen Medicines Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 126,094 | 150,114 | 150,578 | 78,349 | 26,296 | 127,143 |
Other Revenue | -0 | - | -0 | -0 | 0 | - |
| 126,094 | 150,114 | 150,578 | 78,349 | 26,296 | 127,143 | |
Revenue Growth (YoY) | -14.72% | -0.31% | 92.19% | 197.95% | -79.32% | 62.48% |
Cost of Revenue | 92,383 | 115,818 | 116,380 | 78,143 | 31,513 | 93,148 |
Gross Profit | 33,711 | 34,295 | 34,198 | 205.9 | -5,217 | 33,994 |
Selling, General & Admin | 55,647 | 52,138 | 66,149 | 67,621 | 43,833 | 26,983 |
Research & Development | 63,612 | 56,835 | 42,817 | 38,561 | 32,780 | 1,029 |
Amortization of Goodwill & Intangibles | 623.13 | 981.74 | 1,291 | 1,181 | 542.9 | 102.32 |
Other Operating Expenses | 930.74 | 793.02 | 872.25 | 733.32 | 760.94 | 690.81 |
Operating Expenses | 135,007 | 124,617 | 129,168 | 117,150 | 90,590 | 31,150 |
Operating Income | -101,296 | -90,322 | -94,970 | -116,944 | -95,807 | 2,844 |
Interest Expense | -27,001 | -1,007 | -631.84 | -9,906 | -21,764 | -5,231 |
Interest & Investment Income | 6,288 | 4,861 | 3,683 | 3,031 | 2,206 | 10,933 |
Earnings From Equity Investments | -3,747 | - | - | -1,210 | -1,734 | - |
Currency Exchange Gain (Loss) | 545.6 | 761.97 | 30.76 | -113.93 | -44.53 | -466.78 |
Other Non Operating Income (Expenses) | 44,676 | -11,780 | -428.55 | 22,216 | -379.06 | -35,343 |
EBT Excluding Unusual Items | -80,535 | -97,486 | -92,316 | -102,926 | -117,523 | -27,264 |
Gain (Loss) on Sale of Investments | -32,845 | 303 | 341.93 | -3,244 | -9,036 | -11,605 |
Gain (Loss) on Sale of Assets | 136.69 | -201.14 | 30.3 | -235.89 | -287.07 | -3.45 |
Asset Writedown | -43,506 | -801.87 | -2,271 | -9,162 | -223.61 | -241.5 |
Other Unusual Items | 8,377 | -503.07 | -1,024 | -42.95 | 7,728 | -2.67 |
Pretax Income | -148,372 | -98,689 | -95,239 | -115,611 | -119,341 | -39,117 |
Income Tax Expense | -884.92 | 1,687 | 2,044 | 473.8 | -111.74 | -6,448 |
Earnings From Continuing Operations | -147,487 | -100,376 | -97,283 | -116,085 | -119,229 | -32,668 |
Net Income to Company | -147,487 | -100,376 | -97,283 | -116,085 | -119,229 | -32,668 |
Minority Interest in Earnings | 96,553 | 42,296 | 41,664 | 17,428 | 25,309 | -13,822 |
Net Income | -50,934 | -58,079 | -55,619 | -98,657 | -93,920 | -46,490 |
Net Income to Common | -50,934 | -58,079 | -55,619 | -98,657 | -93,920 | -46,490 |
Shares Outstanding (Basic) | 290 | 258 | 236 | 201 | 173 | 57 |
Shares Outstanding (Diluted) | 290 | 258 | 236 | 202 | 173 | 57 |
Shares Change (YoY) | 16.43% | 9.40% | 16.69% | 16.73% | 206.64% | 24.06% |
EPS (Basic) | -175.48 | -224.79 | -235.50 | -490.37 | -541.72 | -822.24 |
EPS (Diluted) | -175.67 | -225.00 | -236.00 | -497.41 | -541.72 | -822.24 |
Free Cash Flow | -34,114 | -57,662 | -83,669 | -133,101 | -119,132 | 19,957 |
Free Cash Flow Per Share | -117.53 | -223.17 | -354.27 | -657.66 | -687.14 | 352.97 |
Gross Margin | 26.73% | 22.85% | 22.71% | 0.26% | -19.84% | 26.74% |
Operating Margin | -80.33% | -60.17% | -63.07% | -149.26% | -364.35% | 2.24% |
Profit Margin | -40.39% | -38.69% | -36.94% | -125.92% | -357.17% | -36.56% |
Free Cash Flow Margin | -27.05% | -38.41% | -55.57% | -169.88% | -453.05% | 15.70% |
EBITDA | -77,212 | -66,017 | -65,899 | -88,552 | -70,545 | 7,152 |
EBITDA Margin | -61.23% | -43.98% | -43.76% | -113.02% | -268.27% | 5.63% |
D&A For EBITDA | 24,085 | 24,305 | 29,071 | 28,392 | 25,262 | 4,308 |
EBIT | -101,296 | -90,322 | -94,970 | -116,944 | -95,807 | 2,844 |
EBIT Margin | -80.33% | -60.17% | -63.07% | -149.26% | - | 2.24% |
Advertising Expenses | - | - | - | - | - | 4,369 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.